With this trial we could show that in patients with triple-negative breast cancer you have to have more information on the tumor. You may want to know the HRD status, homologous recombination deficiency status, and you also may want to know the BRCA status. Because if you combine both informations you can actually offer a very effective, highly effective therapy with a combination of a niraparib, PARP inhibitor, and carboplatin...
With this trial we could show that in patients with triple-negative breast cancer you have to have more information on the tumor. You may want to know the HRD status, homologous recombination deficiency status, and you also may want to know the BRCA status. Because if you combine both informations you can actually offer a very effective, highly effective therapy with a combination of a niraparib, PARP inhibitor, and carboplatin. But in those patients who are HR-positive and BRCA-negative, you also see that a traditional chemotherapy regimen called TAC, a taxane-anthracycline-cyclophosphamide combination is highly effective and increases the rate of complete and near-complete pathologic remissions to more than 70%, which I think is remarkable.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
